Clinical Trial Detail

NCT ID NCT03535740
Title A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Ariad Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Brigatinib

Age Groups: adult senior

Additional content available in CKB BOOST